last decade immunecheckpoint inhibitor target pd1pdl1 pathway revolutionize standard care several type tumour act stemlike cell expand tumourspecific transitory effector cell find describe provide basis development new generation pd1cistargeted il2rβγ agonist preferentially target antigenspecific stemlike cell expand alternative population better effector cell enhance therapeutic potential treatment cancer chronic infection blood sample healthy volunteer obtain blood donation centre zurich switzerland approval cantonal ethic committee zurich pbmcs isolate blood different healthy donor use density gradient centrifugation histopaque1077 sigma cell culture rpmi1640 gibco supplement 10 heatinactivated fbs gibco glutamax gibco 1 penicillinstreptomycin 100× gibco human cd4 cell sort use cd4 selection miltenyi bead system follow manufacturer 's instruction thereafter cell label cfse 5 μm 5 min room temperature ebioscience ctv 5 μm 5 min room temperature thermo scientific measure cell proliferation cd4 cell seed plate precoated anticd3 antibody 1 μg ml clone okt3 biolegend overnight 4 °c addition soluble anticd28 antibody 1 μg ml clone cd28.2 biolegend cell culture 3 induce activation upregulation pd1 receptor surface cd4 cell spleen c57bl6 mouse homogenize singlecell suspension mash spleen 10008m cell strainer erythrocyte lysed ack ammonium chloridepotassium lysis buffer 5 min 4 °c cd4 cell sort cd4 negativeselection miltenyi bead system follow manufacturer 's instruction cd4 cell seed plate precoated anticd3anticd28 antibody 5 μg ml clone 1452c11 biolegend 5 μg ml clone 37.51 biolegend activate 3 d. 3 vitro activation cell collect wash multiple time remove endogenous il2 portion cfselabelled cell expose 10 08g ml parental antipd1 antibody block pd1 epitope 30 min room temperature thereafter unbind antibody wash away ass il2r signal stat5p human cell follow treatment antipd1pretreated untreated cell expose increase concentration pd1il2v fapil2v fapil2 superkine analogue 12 min 37 °c investigate cistrans bind pd1il2v antipd1pretreated untreated cfselabelled cell cocultured 1:1 untreated ctvlabelled cell cell expose 12 min 37 °c 0.1 μg ml 630 pm treatment fusion protein mouse ex vivo experiment cell treat increase do mupd1il2v mufapil2v 30 min 37 °c directly treatment cell fix phosphoflow fix buffer bd incubate 30 min 37 °c cell permeabilized overnight 80 °c phosphoflow permbuffer iii bd stain 30 min 4 °c antistat5paf647 antibody clone 47py694 bd bioscience 1:20. cd4cd25cd127 cell isolate human peripheral blood twostep regulatory cell isolation kit miltenyi parallel cd4cd25 cell isolate collect negative fraction selection cd25 cell miltenyi follow enrichment cd4 cell miltenyi cell label cfse cell label ctv track proliferation population pd1 il2rβ receptor quantification pd1il2v bind competition cell cocultured 1:1 ratio plate precoated anticd3 antibody 1 μg ml clone okt3 biolegend soluble anticd28 antibody 1 μg ml clone cd28.2 biolegend 3 stimulation competitive bind assay conduct 1 μg ml 6.3 nm either parental antipd1 antibody pd1il2v directly label af647 cell incubate directly couple antibody 30 min 4 °c fix cellfix bd suppression assay rescue granzyme b production follow treatment pd1il2v measure coculturing cell together cell 2:1 ratio 5 presence absence treatment irradiate 40 gy feeder unrelated donor use elicit allospecific stimulation suppression cell calculate follow formula cytokine level cytokine secrete cell presence cell ± treatment cytokine level cytokine secrete cell absence cell without treatment sort ctvlabelled human polyclonal cd4 cell activate soluble anticd3 antibody 1 μg ml presence irradiate 40 gy feeder cell donor 1:1 ratio increase concentration treatment antibody aldesleukin proleukin novartis 5 gmcsf secretion measure elisa biolegend follow manufacturer 's instruction intracellular flow cytometry stain accumulation cytokine golgi complex induce restimulating cell ionomycin 500 ng ml phorbol 12myristate 13acetate pma 50 ng ml together protein transport inhibitor 1 μl golgiplug golgistop bd 5 h stain cd4 cell activate 3 expose increase equimolar concentration pd1il2v pembrolizumab nonblocking pd1il2v 30 min 4 °c wash step cell incubate additional 30 min 4 °c saturate concentration 10 μg ml parental antipd1 antibody conjugate directly af647 use generate pd1il2v cell fix cellfix bd additional wash. cell stain pb antibody cellsurface marker 30 min 4 °c livedead status either aqua dead cell stain invitrogen last 10 min incubation fixable viability dye efluor 780 ebioscience 30 min 4 °c intracellular stain cell permeabilized facs permeabilization buffer fixationpermeabilization bd bioscience foxp3 transcription factor fixation kit ebioscience incubate antibody specific cytokine 60 min 4 °c follow antibody mix use 1 antibody human protein antipd1 2.5 μg ml clone eh12.2h7 biolegend antiil2rβ 2.5 μg ml clone tu27 biolegend isotype control 2.5 μg ml clone mopc21 biolegend anticd4 1:50 clone rpat4 ebioscience antigmcsf 1:100 clone bvd221c11 biolegend antigranzyme b 1:100 gb11 bd bioscience antiifnγ 1:100 clone 4s.b3 ebioscience 2 antibody mouse protein antipd1 2.5 μg ml clone 29f.1a12 syngeneic mouse clone eh12.2h7 human pd1transgenic mouse biolegend antiil2rβ 2.5 μg ml clone 5h4 biolegend isotype control 2.5 μg ml clone rtk2758 biolegend antitcrβ 1:200 clone h57597 biolegend anticd8 1:200 clone 536.7 biolegend anticd4 1:100 clone gk1.5 biolegend anticd45 1:300 clone 30f11 biolegend anticd62l 1:200 clone mel14 biolegend anticd44 1:200 clone im7 bd antifoxp3 1:100 clone 150d biolegend number pd1 il2rβ receptor quantify cell surface pbmcs tils human pd1transgenic mouse bear panc02h7fluc tumour activate human cell pe fluorescence quantitation kit bd follow manufacturer 's instruction pelabelled monoclonal antibody 2.5 08g ml use quantify receptor interest gate population interest cell pe quantibrite bead fix follow protocol fluorescence data acquire use set number receptor quantify follow kit 's instruction ex vivo bind pd1il2v fapil2v fapsuperkine analogue perform incubate 630 pm construct 30 min pbmcs healthy donor wash step cell incubate additional 30 min 4 °c pelabelled antibody recognize pglala mutation fc portion primary antibody together panel antibody characterize phenotype immunecytokine target cell anticd3 1:100 clone okt3 biolegend anticd4 1:100 clone okt4 bd bioscience anticd8 1:100 clone rpat8 bd bioscience antitim3 1:20 clone f382e2 biolegend anticd218a 1:100 clone h44 biolegend anticd56 1:20 clone ncam16.2 bd bioscience antitcf1 1:100 c63d9 cell signal technology antifoxp3 1:50 clone 206d biolegend antipd1 1:100 clone d4w2j cell signal technology follow polyclonal goat antirabbit antibody 1.50 biolegend sample acquisition perform bd bioscience lsrii fortessa symphony a5 instrument facsdiva v9.1 bd bioscience data analyse use flowjo software v10.8.1 bd bioscience six 8weekold female c57bl6j cd45.1 congenic mouse purchase jackson laboratory follow house condition mouse use 12hlight cycle 7:00 7:00 pm temperature 6874 °f humidity 3070 g m. chronically lcmvinfected mouse generate follow mouse transiently deplete cd4 cell inject 300 μg gk1.5 antibody intraperitoneally 2 infection day infection follow infection mouse 2 × 10 pfu lcmv clone 13 intravenously tail vein titre virus determine plaque assay vero e6 cell animal experiment perform accordance national institute health emory university institutional animal care use committee guideline orthotopic subcutaneous syngeneic model use ass vivo efficacy mupd1il2v compare single agent mupd1 mufapil2v combination c57bl6j mouse subcutaneous syngeneic model use ass vivo efficacy pd1il2v compare pembrolizumab aldesleukin combination human pd1transgenic c57bl6j mouse university oxford survival tumour growth inhibition readout orthotopic subcutaneous model respectively brief 6 8weekold female c57bl6j mouse charles river inoculate 1 × 10 panc02h7fluc cell inject pancreas pancreatic orthotopic model 5 × 10 panc02h7fluc cell inject subcutaneously subcutaneous model mouse maintain specificpathogenfree condition daily cycle 12 h light12 h darkness accord guideline temperature 22 °c darklight cycle 12 h humidity 50 gvsolas felasa food water provide ad libitum continuous health monitor carry experimental study protocol review approve veterinary department canton zurich mouse randomize different treatment group therapy start evidence tumour growth visible target organ bioluminescence 7 tumour cell inoculation orthotopic model tumour reach average volume 200 mm measure calliper subcutaneous model treatment administer intravenously follow do investigate mupd1il2v 0.5 1 mg kg mufapil2v 2.5 mg kg mupd1 10 mg kg pd1il2v 0.5 mg kg pembrolizumab 10 mg kg aldesleukin 900,000 iu kg twice daily termination criterion orthotopic model kill animal sickness locomotion impairment median overall survival define experimental day 50 animal kill kaplanmeier survival curve pairwise logrank test use compare survival animal treatment group subcutaneous model tumour growth inhibition use readout test significant difference group mean multiple comparison standard anova oneway anova use dunnett 's method jmp statistical software program use analysis orthotopic model pancreatic carcinoma cell line panc02h7fluc use orthotopic pancreatic model brief median laparotomy perform deep general anaesthesia pancreas expose aliquot 1 × 10 panc02h7fluc cell inject pancreas pancreas replace abdominal wall close therapy start 7 tumour cell inoculation solid tumour pancreas observe mean bioluminescence image subcutaneous model pancreatic carcinoma cell line panc02h7fluc 5 × 10 cell inject subcutis leave flank tumour volume measure use calliper tumour volume calculate formula therapy start tumour volume reach 150200 mm cd8 depletion study mouse bear panc02h7fluc subcutaneous tumour administer intravenously antimouse cd8 antibody invivoplus antimouse cd8α clone 2.43 bioxcell 5 mg kg three time week 1 week first administration therapy depletion mouse cd8 cell evaluate blood flow cytometry start therapy subcutaneous melanoma syngeneic model use ass vivo efficacy mupd1il2v compare single agent mupd1 mufapil2v combination c57bl6j mouse tumour growth inhibition survival rate readout subcutaneous model brief 6 8weekold female c57bl6j mouse charles river inoculate subcutaneously 2 × 10 b16f10ova cell b16 cell line overexpressing ovum protein describe previously panc02h7fluc model mouse maintain specificpathogenfree condition daily cycle 12 h light12 h darkness accord guideline gvsolas felasa food water provide ad libitum continuous health monitor carry experimental study protocol review approve veterinary department canton zurich tumour volume measure use calliper tumour volume calculate formula mouse randomize 10 tumour inoculation different treatment group basis tumour size therapy start 11 tumour inoculation treatment administer subcutaneously week follow do investigate mupd1il2v 0.5 mg kg mufapil2v 1.5 3 mg kg combination mupd1 10 mg kg fapil2v 1.5 mg kg survival rate curve termination criterion kill animal either tumour size tumour ulceration tumour growth inhibition additional readout test significant difference group mean multiple comparison standard anova oneway anova use dunnett 's method graphpad prism software v8 use graphical representation analysis subcutaneous fibrosarcoma syngeneic model also use ass vivo efficacy mupd1il2v compare single agent mupd1 mufapil2v combination c57bl6j mouse cro antineo lyon france tumour growth inhibition readout subcutaneous model brief 6 8weekold female c57bl6j mouse charles river inoculate 5 × 10 mca205 cell inject subcutaneously mouse maintain specificpathogenfree condition continuous health monitor accord guideline animalerie commune scar rockefeller lyon france mouse randomize different treatment group therapy start tumour reach average volume 100 mm measure calliper subcutaneous model treatment administer intravenously follow do investigate mupd1il2v 1 2 mg kg mufapil2v 2 mg kg mupd1 3 mg kg tumour volume measure use calliper calculate formula tumour growth inhibition use readout test significant difference group mean multiple comparison standard anova oneway anova use dunnett 's method jmp statistical software program use analysis generation riptag5 mouse previously describe riptag5 mouse study c57bl6n background charles river male age 21 31 week animal experiment conduct accord protocol approve veterinary authority canton vaud swiss law enrol riptag5 mouse trial mouse 22 week age display blood glucose level 7 mm screen presence pannet islet tumour ultrasound image use vevo2100 system ms550d 40mhz transducer visual sonic riptag5 mouse randomly assign different treatment group basis cumulative tumour burden average start tumour burden 27 mm average start age 26 week average start glucose level 5.5 mm tumour monitor ultrasound image every 2 week every 4 week complete responder maximum 16 week follow start treatment blood glucose level monitor weekly use accuchek glucometer roche criterion endpoint define tumour burden 50 mm 2 4fold increase progression relapse tumour hypoglycaemia blood glucose level 3 mm health status therapy administer intraperitoneal injection follow amount per mouse mupd1 250 μg week dp47muil2v untargeted muil2v 25 μg week pd1il2v 25 μg week duration 8 week histological analysis tissue sample collect fix 10 formalin sigma later process ffpet leica 1020. fourmicrometre paraffin section subsequently cut microtome leica rm2235 haematoxylin eosin stain perform automate leica system follow manufacturer 's instruction mouse pd1 immunohistochemistry perform antimouse pd1 1:250 clone af1021 rd system mouse granzyme b stain perform antimouse gzmb 1:250 clone ab4059 abcam cd3 1:100 clone sp7 diagnostic biosystems cd8 1:300 clone 4sm15 ebiosciences cell stain perform leica autostainer leica st5010 follow manufacture 's protocol section counterstained haematoxylin sigmaaldrich slide scan use olympus vs120l100 virtual slide microscope scanner quantification positive cell scan image perform definiens software whole scan upload tissue developer module necrotic area exclude segmentation analysis second threshold set recognize brown stain target cell algorithm cell quantification percentage positive area subsequently automatically run output data transfer graphpad prism v8 analysis significance standard anova oneway anova dunnett 's correction vero e6 cell obtain american type culture collection mouse pancreatic cancer cell line panc02h7fluc generate roche glycart b16ova cell line purchase proqinase mca205 mouse fibrosarcoma cell line purchase sigmaaldrich derive 3methylcholanthreneinduced fibrosarcoma c57bl6 mouse tumour maintain vivo serial subcutaneous transplantation syngeneic mouse singlecell suspension prepare solid tumour enzymatic digestion.from cell mca205 cell line establish maintain vitro vero e6 cell authenticate mca205 b16ova panc02h7fluc cell authenticate morphology pcr assay speciesspecific primer mca205 cell test negative infectious disease use mouse essential clear panel charles river animal diagnostic service negative mycoplasma contamination batch panc02h7fluc b16ova cell line routinely test house mycoplasma negative lymphocyte isolate blood spleen lung describe previously brief spleen dissociate pass 70μm cell strainer corn lung treat 1.3 mm edta hb 30 min 37 °c shake 200 r.p.m. follow treatment 150 u ml collagenase thermo fisher scientific rpmi1640 contain 5 fbs 1 mm mgcl 1 mm cacl 60 min 37 °c shake 200 r.p.m collagenasetreated lung tissue homogenize filter 70μm cell strainer lymphocyte lung purify use 4467 percoll gradient 800 g 20 °c 20 min mouse kill accord animal welfare guideline tumour tissue blood isolate animal facility tumour tissue transfer pb disrupt use manual scissor miltenyi gentle mac machine subsequently digest enzyme mix consist rpmi 10 mg ml dnase sigmaaldrich 0.25 mg ml liberase sigmaaldrich.after 30 min digestion 37 °c tissue mix filter 7008m filter resuspend singlecell suspension appropriate volume subsequent stain fluorescently label antibody blood transfer heparin tube red blood cell lysed erythrocyte lysis buffer red blood cell lysis cell resuspend singlecell suspension appropriate volume subsequent stain fluorescently label antibody lymphocyte mechanically isolate drain lymph node pestle filter 7008m filter resuspend singlecell suspension appropriate volume subsequent stain fluorescently label antibody antibody flow cytometry purchase bd bioscience biolegend thermo fisher scientific cell signal technology rd system dgp3341 dgp276286 tetramers prepare house use detect lcmvspecific cd8 cell streptavidinpe streptavidinapc purchase thermo fisher scientific dead cell exclude use livedead fixable nearir yellow dead cell stain kit thermo fisher scientific cellsurface stain antibody add cell dilution 1:20 1:500 pb supplement 2 fbs 0.1 sodium azide 30 min ice cell wash three time fix 2 paraformaldehyde detect cytokine production 1 × 10 splenocytes stimulate pool nine lcmvspecific peptide 200 ng ml gp3341 gp7077 gp92101 gp118125 gp276286 np166175 np205212 np235249 np396404 96well roundbottom plate 5 h 37 °c co incubator presence golgiplug bd bioscience sample acquire canto ii lsr ii facsymphony a3 instrument bd bioscience facsdiva v9.1 bd bioscience data analyse use flowjo v9.9.6 v10.8.1 bd bioscience singlecell suspension tumour blood stain follow antibody fixable viability dye efluor 455uv 1:500 af700 anticd45 1:300 clone 30f11 biolegend percpcy5.5 antitcrβ 1:200 clone h57597 biolegend apccy7 anticd8 1:200 clone 536.7 biolegend pecy7 anticd4 1:200 clone gk1.5 biolegend fitc anticd62l 1:200 clone mel14 biolegend pe anticd127 1:100 clone a7r34 biolegend bv421 anticd4 1:200 clone gk1.5 biolegend af647 antigranzyme b 1:100 clone gb11 biolegend bv786 antiifnγ 1:100 clone xmg1.2 biolegend pecy7 antitnfα 1:100 clone mp6xt22 biolegend bv421 antifoxp3 1:100 clone mf14 biolegend af647 anticd39 1:200 clone duha59 biolegend af700 antigranzyme b 1:100 clone qa16a02 biolegend pecy7 antiki67 1:300 clone 16a8 biolegend pecy7 antipd1 1:200 clone rmp130 biolegend bv711 anticd25 1:200 clone rmt323 biolegend pedazzle594 antitigit 1:100 clone 1g9 biolegend bv605 antiifnγ 1:100 clone xmg1.2 biolegend bv421 antitnfα 1:100 clone mp6xt22 biolegend af488 anticd107a 1:100 clone 1d4b biolegend bv510 anticd44 1:200 clone im7 bd bioscience buv805 anticd45 1:100 clone 30f11 bd bioscience bv786 antitcrβ 1:100 clone h57597 bd bioscience buv496 anticd4 1:100 clone rm45 bd bioscience buv395 anticd8 1:100 clone 536.7 bd bioscience buv737 antipd1 1:100 clone rmp130 bd bioscience pecf594 anticd25 1:100 clone pc61 bd bioscience bv650 antitim3 1:100 clone 5d12 bd bioscience pe antitcf1 1:100 clone s33966 bd bioscience bv650 antilag3 1:100 clone c9b7w bd bioscience bv510 antislamf6 1:50 clone 13g3 bd bioscience fitc anticd218a 1:50 clone rea947 miltenyi detection ovaspecific cd8 cell perform use apclabelled dextramer h2kb siinfekl immudex 1:100. stain dextramer perform use 0.1 bsa pb intracellular stain cell fix permeabilized use foxp3 transcription factor stain buffer set ebioscience transcription buffer set bd detection cytokine tumour cell suspension restimulated 6.25 ng ml pma sigmaaldrich 1.87 μg ml ionomycin sigmaaldrich 5 h 37 °c 1 h restimulation golgiplug bd golgistop bd add cell suspension antigen restimulation tumour cell suspension restimulated 0.1 08g ml gp100 siinfekl peptide 5 h 37 °c anticd107a antibody add together peptide 5 h 37 °c 1 h restimulation golgiplug bd golgistop bd add cell suspension discrimination live cell dead cell perform use dapi sigmaaldrich fixable viability dye efluor 780 ebioscience livedead apccy7 ebioscience sample acquire bd lsrii fortessa bd facsymphony a5 instrument use facsdiva v9.1 bd bioscience data obtain analyse use flowjo v10.8.1 bd bioscience cell sort perform facsaria ii bd bioscience adoptive transfer experiment two pd1expressing cd8 cell subset pd1cxcr5tim3 pd1cxcr5tim3 sort pool spleen n 4060 chronically lcmvinfected mouse rnaseq analysis lcmvspecific cd8 cell mupdl1 mupd1il2v mupdl1 mupd1il2v therapy chronically lcmvinfected mouse 40 infection n 118 leave untreated treat 2 week dgp33cd8 cell sort pool spleen obtain least 2 × 10 cell naive cd44 cd8 cell sort pool spleen uninfected mouse n 23. sample purity greater 95. singlecell tumour suspension keep ice stain sort procedure cell suspension 35 tumour treatment group stain follow antibody af700 anticd45 1:100 clone 30f11 biolegend bv711 anticd8 1:100 clone 536.7 biolegend bin channel bv605 anticd4 1:100 clone gk1.5 biolegend bv605 anticd11c 1:100 clone n418 biolegend discrimination live cell dead cell perform use livedead apccy7 ebioscience 65086514 1:500 nonfixed sample cell incubation 20 min cell wash twice filter 4008m cell strainer sort facsaria iii instrument acquire facsdiva enrich viable single cd45cd8cd11ccd4 cell pdl1 blockade 200 μg mouse mupdl1 antibody dapg mutation roche administer intraperitoneally chronically lcmvinfected mouse every 3 2 week appropriate isotype control mouse igg1 isotype control mopc21 bioxcell administer untreated mouse mufapil2 therapy 1 mg kg mufapil2wt mufapil2v administer intraperitoneally chronically lcmvinfected mouse twice weekly 2 week mupd1il2v therapy 1 mg kg mupd1il2v administer intraperiotenally chronically lcmvinfected mouse twice weekly 2 week cell two cd8 cell subset 48 × 10 cell pd1cxcr5tim3 pd1cxcr5tim3 isolate chronically lcmvinfected mouse cd45.2 transfer infectionmatched recipient mouse cd45.1 follow mupd1il2v treatment 2 week total rna extract use rneasy micro kit qiagen directzol rna microprep kit zymo research accord manufacture 's protocol emory integrate genomics core house preparation standard rnaseq library perform hudson alpha emory yerkes nonhuman primate research center nprc genomics core brief rna amplification perform use nugen ovation rnaseq v2 kit clontech smartseq v4 ultra low input rna kit takara bio amplify cdna fragment sample prepare use kapahyper prep kit nextera xt dna library preparation kit illumina pool library sequence illumina novaseq 6000 100bp pairedend read tumour lymph node digest previously describe 110 mio cell store liquid nitrogen ibidi freeze medium sample randomize process four different batch ten sample tumour lymph node process separately thaw batch sample cell stain mix flow cytometry oligonucleotidelabelled antibody table 1 sort cd8 cell perform scrnaseq brief cell wash pb evaluation cell number viability use nexcelom cellometer auto 2000. approximately one mio cell per sample resuspend 50 08l pb incubate 5 08l mouse trustain fcx fc block reagent biolegend mix flow cytometry oligonucleotidelabelled antibody add cell volume 50 08l final volume 100 08l incubation 30 min 4 °c cell wash three time pb resuspend 500 08l pb obtain concentration approximately 1 × 10 cell per ml cell filter 4008m cell strainer sort bd facsaria iii system cell number viability sort cell determine use nexcelom cellometer auto 2000 total 10,000 viable cell per sample load 10x genomics chromium controller cdna library preparation perform accord manufacturer 's indication scrnaseq 5 v2 kit tcr feature barcoding result library sequence illumina novaseq 6000 sequencer accord 10x genomics recommendation r1 26 i7 10 i5 10 r2 90 depth approximately 20,000 read per cell gex library 5,000 read per cell tcr feature barcoding library read map grcm38mm10 genome hisat2 v2.1.0 gene expression quantify featurecounts v1.5.2 deseq2 ref v1.24.0 use normalize library size calculate differential expression across group gene consider differentially express two group adjust p value 0.05 average expression 20 normalize count across sample pca perform detect gene use regularize log transformation deseq2 rnaseq data visualize use prism software v9.3.1 graphpad complexheatmap r package v2.2.0 fastq file align mouse transcriptome mm102020a use cellranger count vdj v6.0.0 parameter 'expectcells 6000 cell show 200 count merge across sample process scanpy besca standard workflow filter perform parameter mingenes 500 mincells 20 mincounts 1000 ngenes 6000 percentmito 0.08 maxcounts \<SEP>0